PDCD1 and nonpapillary renal cell carcinoma: The use of the anti-programmed cell death-1 (PD-1) pembrolizumab as an adjuvant treatment strategy after radical surgery showed both statistically significant, as well clinically meaningful, improved disease-free survival (DFS) along with a meaningful but modest benefit in terms of overall survival (OS) when compared with placebo in patients with ccRCC at a higher risk of relapse [9].